Clinical Analysis of Lacosamide Monotherapy in the Treatment of Self-Limited Epilepsy with Centrotemporal Spikes
Jun Feng,Liya Zhang,Jihong Tang,Bingbing Zhang,Xiao Xiao,Xiaoyan Shi
DOI: https://doi.org/10.2147/ndt.s452784
IF: 2.989
2024-03-05
Neuropsychiatric Disease and Treatment
Abstract:Jun Feng, Liya Zhang, Jihong Tang, Bingbing Zhang, Xiao Xiao, Xiaoyan Shi Department of Neurology, Children's Hospital of Soochow University, Suzhou, Jiangsu, 215025, People's Republic of China Correspondence: Liya Zhang; Jihong Tang, Email ; Objective: To evaluate the efficacy and safety of lacosamide (LCM) monotherapy in the treatment of self-limited epilepsy with centrotemporal spikes (SeLECTS). Methods: In this study, 89 children with SeLECTS who were treated with LCM monotherapy in the Children's Hospital Affiliated to Soochow University from June 2019 to June 2021 were included. Clinical seizures and spike wave index (SWI) on video EEG during slow-wave sleep were evaluated before and after treatment. The role of LCM monotherapy in improving SWI, controlling clinical seizures and improving cognition was analyzed, and corresponding adverse reactions were documented. Results: There were 52 males and 37 females in this group, with an average age of 7.6 ± 2.1 years. The total effective rate was 93.83% and at 18 months of treatment, the cumulative control rate was 85.19%, the retention rate was 91.01% and the effective rate in terms of EEG spike index was 72.92%, all of which showed a high rate; there was no statistically significant difference in intelligence quotient before and after treatment ( P > 0.05). In addition, it was found in the study that the earlier the age of onset, the less obvious the improvement in SWI after LCM treatment; the lower the baseline seizure frequency, the more significant the improvement in SWI after LCM treatment. Conclusion: LCM monotherapy had curative effect and adverse reactions for SeLECTS, with no negative impact on cognition. These significant findings indicate that LCM is likely to become a widely prescribed ASM for the treatment of SeLECTS. Meanwhile, the onset age and baseline seizure frequency had certain value in judging prognosis and predicting curative effect. Keywords: lacosamide, epilepsy, self-limited epilepsy with centrotemporal spikes, efficacy, safety Epilepsy is a common neurological disorder in children and adolescents, and about three-quarters of patients with epilepsy have onset in childhood, with a prevalence of about 0.3% to 0.9%, of which self-limited epilepsy with centrotemporal spikes (SeLECTS) is the most common focal epilepsy for children. 1 The typical interictal EEG pattern is a high-amplitude spike or sharp wave with a prominent following slow wave appearing singly or in groups most commonly located at the midtemporal and central region. Epileptic discharges on EEG increased significantly after children with SeLECTS fell asleep. In a few children, spike and wave index (SWI) can reach 50% or even more than 80% during non-rapid eye movement sleep (NREM) period. 2 Currently, there are a variety of antiseizure medications (ASMs) that can treat SeLECTS, 3 but there is no consensus on which ASM to use for this epilepsy. However, several studies have investigated various ASMs in the treatment of SeLECTS, such as Levetiracetam and oxcarbazepine, which are suggested to be effective and well-tolerated drugs. 4 But 25% to 30% of pediatric patients still have poor response to medical treatment, incomplete control of seizures, and even develop into drug-refractory epilepsy. 5 In addition, some studies 6–8 have shown that children with SeLECTS have a certain degree of cognitive impairment. Several studies have investigated the impact of treatment in cognitive profile, such as levetiracetam, which is suggested a nonworsening of the cognitive profile, on the contrary, cognitive scores also improved over time. 9 To protect the learning ability of school-age child, it is particularly important to get timely and effective treatment and choose drugs that have no negative effects on cognition. LCM is a third-generation antiseizure medication that was available clinically in 2008. LCM has a novel mechanism of action and anticonvulsant effects by selectively acting on the slow voltage-gated sodium channel inactivation. Unlike conventional sodium channel blockers, LCM does not affect fast inactivation. 10,11 A large number of clinical studies have confirmed that LCM has good seizure control efficacy with less side effects in patients with epilepsy as adjunctive therapy or monotherapy. Based on the findings of three randomized controlled trials, LCM was initially approved as an adjunctive therapy for partial-onset (focal) seizures, whether with or without secondary generalization. 10–13 The further open-label extensions showed that LCM had a sustained efficacy and good long-term safety. 14 The efficacy and safety of lacosamide in treatment in patients with epilepsy is con -Abstract Truncated-
psychiatry,clinical neurology